Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Ariad Pharmaceuticals to similar companies based on the strength of its valuation, institutional ownership, earnings, dividends, profitability, analyst recommendations and risk.
Institutional and Insider Ownership
87.0% of Ariad Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 8.2% of Ariad Pharmaceuticals shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Ariad Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ariad Pharmaceuticals Competitors||$284.49 million||$34.10 million||67.35|
Ariad Pharmaceuticals’ competitors have higher revenue and earnings than Ariad Pharmaceuticals. Ariad Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and target prices for Ariad Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ariad Pharmaceuticals Competitors||884||3270||11759||235||2.70|
Ariad Pharmaceuticals presently has a consensus target price of $22.00, indicating a potential downside of 8.30%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.19%. Given Ariad Pharmaceuticals’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Ariad Pharmaceuticals has less favorable growth aspects than its competitors.
This table compares Ariad Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ariad Pharmaceuticals Competitors||-5,226.85%||-213.68%||-38.94%|
Ariad Pharmaceuticals competitors beat Ariad Pharmaceuticals on 7 of the 11 factors compared.
Ariad Pharmaceuticals Company Profile
ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).
Receive News & Ratings for Ariad Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.